Integrum AB, Mölndal, Sweden, received patent approval in the United States for components and design features of its OPRA Implant System, a bone-anchored prosthesis system based on osseointegration. The approval includes elements that were implemented in 2017 and granted premarket approval by the Food and Drug Administration in 2020. The patent period extends until 2044.
The patent incorporates claims covering the system, including the anchoring solution for attaching a prosthesis as well as the abutment and the abutment screw. The claims extend beyond transfemoral applications to include treatment in other types of long bone prosthetic applications, such as the upper arm or lower leg.
The claims also cover design features for the connection between the abutment and the fixture, allowing a pathway for communication of physical and biophysical signals between the inside and outside of the human body.
